Johnson & Johnson starts 60,000-person final stage test of Covid-19 vaccine

Johnson & Johnson is testing its single-dose Covid-19 vaccine on 60,000 people on three continents. The Wall Street Journal reports that Johnson & Johnson "could learn pivotal results from the trial by early next year, which if positive could lead to government authorization of the vaccine for emergency use soon afterward.